Biodesix Inc (BDSX) stock has reached a new 52-week low, trading at $1.11, as the company faces ongoing market headwinds. According to InvestingPro data, despite strong revenue growth of ~49% over the last twelve months, the company is quickly burning through cash with negative EBITDA of -$29.26M. This latest price point reflects a significant downturn from the previous year, with the stock experiencing a 1-year change of -41.32%. While the company maintains strong liquidity with a current ratio of 3.4, investors are closely monitoring Biodesix's performance as it navigates through a challenging period. InvestingPro analysis suggests the stock may be slightly undervalued at current levels, with additional insights available in the comprehensive Pro Research Report, part of InvestingPro's coverage of over 1,400 US stocks.
In other recent news, Biodesix reported strong growth in its Q3 earnings call. The diagnostic company saw a 35% year-over-year increase in revenue, reaching $18.2 million, with lung diagnostic testing revenue climbing 40% to $17.2 million. Despite operational challenges, the company improved its net loss by 6% to $10.3 million and upheld a robust gross margin of 78.4%.
These recent developments also include Biodesix's reiteration of its full-year revenue guidance, which remains at $70 million to $72 million. The company is targeting an adjusted EBITDA breakeven in the second half of 2025.
While operational expenses rose to $22.6 million due to increased sales and marketing efforts, Biodesix ended the quarter with $31.4 million in cash and announced a new $50 million ATM program. The company also introduced new coverage for Nodify tests and presented significant data at the CHEST conference.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.